bendamustine hydrochloride has been researched along with Lymphoma, T Cell, Peripheral in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Agbetiafa, K; Amorim, S; Aubrais, R; Banos, A; Bellal, M; Besson, C; Bijou, F; Bonnet, C; Bouabdallah, K; Brice, P; Chartier, L; Chauchet, A; Cluzeau, T; Daguindau, N; Damaj, G; Delapierre, B; Durot, E; Fouillet, L; Gaulard, P; Herbaux, C; Laribi, K; Le Calloch, R; Parrens, MC; Schiano, JM; Sibon, D; Tournilhac, O | 1 |
| Egle, A; Greil, R; Jäger, U; Keil, F; Lehner, B; Magnes, T; Melchardt, T; Panny, M; Sillaber, C; Simonitsch-Klupp, I; Skrabs, C; Staber, P; Wagner, SM | 1 |
| Do, YR; Hong, JY; Hyun, SY; Jo, JC; Kim, JA; Kim, MK; Kim, WS; Koh, YI; Lee, SS; Lee, WS; Oh, YH; Park, BB; Suh, C; Won, JH; Yang, DH | 1 |
| Abarah, W; Bachy, E; Braun, T; Broussais, F; Cartron, G; Choufi, B; Clavert, A; Damaj, G; Fornecker, LM; Fruchart, C; Gac, AC; Garidi, R; Gaulard, P; Gyan, E; Herbaux, C; Houot, R; Jaccard, A; Joly, B; Le Bras, F; Maisonneuve, H; Malak, S; Marin, E; Martignoles, JA; Morschhauser, F; Parcelier, A; Pham, AD; Reboursiere, E; Rossi, C; Safar, V; Schirmer, L; Sibon, D; Tilly, H; Tournilhac, O; Tricot, S | 1 |
| Cheson, BD | 1 |
| Banos, A; Béné, MC; Bouabdallah, K; Bubenheim, M; Cartron, G; Choufi, B; Cony-Makhoul, P; Damaj, G; Diouf, M; Gressin, R; Gyan, E; Houot, R; Jaccard, A; Joly, B; Lamy, T; Le Gouill, S; Marolleau, JP; Martin, A; Park, S; Saad, A; Sanhes, L; Schiano-de Collela, JM; Schmidt-Tanguy, A; Tournilhac, O; Vilque, JP; Voillat, L | 1 |
1 review(s) available for bendamustine hydrochloride and Lymphoma, T Cell, Peripheral
| Article | Year |
|---|---|
Novel therapies for peripheral T-cell non-Hodgkin's lymphomas.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Lymphoma, T-Cell, Peripheral; Nitrogen Mustard Compounds; Pyrazines; Vidarabine | 2009 |
2 trial(s) available for bendamustine hydrochloride and Lymphoma, T Cell, Peripheral
| Article | Year |
|---|---|
A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial).
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carboplatin; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Progression-Free Survival; Salvage Therapy; Thrombocytopenia; Young Adult | 2019 |
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitrogen Mustard Compounds; Prognosis; Prospective Studies; Remission Induction; Salvage Therapy; Survival Rate | 2013 |
3 other study(ies) available for bendamustine hydrochloride and Lymphoma, T Cell, Peripheral
| Article | Year |
|---|---|
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Chronic Disease; Hodgkin Disease; Humans; Lymphoma, T-Cell, Peripheral; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2023 |
Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Child; Combined Modality Therapy; Female; Hodgkin Disease; Humans; Induction Chemotherapy; Ki-1 Antigen; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Prognosis; Treatment Outcome; Young Adult | 2020 |
Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; France; Humans; Kaplan-Meier Estimate; Logistic Models; Lymphatic Metastasis; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Proportional Hazards Models; Recurrence; Retrospective Studies; Time Factors; Treatment Outcome | 2016 |